Skip to main content

Advertisement

SpringerLink
Log in

What is the true risk of a pharmacokinetic drug–drug interaction?

  • Editorial
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Saari TI, Laine K, Bertilsson L, Neuvonen, PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol DOI 10.1007/s00228-007-0350-0

  2. Andrén L, Andreasson Å, Eggertsen R. Interaction between a commercially available St John’s Wort product (Movina®) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol DOI 10.1007/s00228-007-0345-x

  3. von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1 infected adults Eur J Clin Pharmacol DOI 10.1007/s00228-007-0344-y

  4. Flaherty JH, Perry HM 3rd, Lynchard GS, Morley JE (2000) Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci 55(10):M554–M559 Oct 2000

    PubMed  CAS  Google Scholar 

  5. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72(6):685–691 Dec 2002

    Article  PubMed  CAS  Google Scholar 

  6. Backman JT, Wang JS, Wen X, Kivisto KT, Neuvonen PJ (1999) Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther 66(4):401–407 Oct 1999

    Article  PubMed  CAS  Google Scholar 

  7. EMEA (2001) Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98) as of July 2001

  8. EMEA (2006) Questions and Answers on the Bioavailability and Bioequivalence Guideline (EMEA/CHMP/EWP/40326/2006) as of July 2006

  9. FDA (2003) Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. Revision 1. March 2003

  10. FDA (2001) Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. January 2001

  11. Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29(8):323–328 Aug 1991

    PubMed  CAS  Google Scholar 

  12. EMEA (1997) Note for Guidance on the Investigation of Drug Interactions (EMEA/CHMP/EWP/560/95) as of December 1997

  13. FDA (2006) Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and Labeling, November 1999; and draft version as of September 2006

  14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425–1435 Apr 7 2005

    Article  PubMed  CAS  Google Scholar 

  15. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15(5):678–682 May 1995

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Gleueler Str. 24, 50931, Cologne, Germany

    Uwe Fuhr

Authors
  1. Uwe Fuhr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Fuhr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fuhr, U. What is the true risk of a pharmacokinetic drug–drug interaction?. Eur J Clin Pharmacol 63, 897–899 (2007). https://doi.org/10.1007/s00228-007-0357-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0357-6

Search

Navigation